All the funding deals in the biotechnology market
Last updated: 13 July 2026
In our biotechnology market deck, you will find everything you need to understand the market
The biotechnology market continues to attract major funding across therapeutics, drug discovery, genetic medicine, and life-science platforms.
We conducted deep research and collected 120 biotechnology funding deals announced from 2024 to 2026.
We refresh this biotechnology market page very often to keep the funding list useful and current.
This chart, featured in our biotechnology market deck, illustrates yearly venture capital funding for biotechnology startups
Summary table of the funding deals for the biotechnology market since 2024
We define the biotechnology market as products and services that apply modern biological science and engineering to create or improve medical and life-science outcomes.
We include biopharma R&D and therapeutics (including biologics, cell/gene therapies, and vaccines), molecular diagnostics, and core life-science research tools and reagents used to generate and analyze biological data.
We exclude routine healthcare delivery, conventional pharmaceuticals and chemicals not enabled by biotechnology, and agriculture/industrial bioapplications unless they are explicitly in scope for the analysis.
We focused exclusively on pure players, defined as companies with at least 70–80% of their business directly tied to the biotechnology market.
Our analysis has been done at a global level with a minimum funding threshold of $300k.
You can also read our detailed analysis to understand how funding activity in the biotechnology market has evolved recently.
If you want a longer-term view, we also have a study of how funding activity in the biotechnology market has changed over the years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the biotechnology market.
| Name | What they do | Amount in $ | Quarter | Source(s) |
|---|---|---|---|---|
| Lycia Therapeutics | Develops protein-degradation medicines for immune and allergic diseases. | $75M | Q2 2026 | Source |
| Oblenio Bio | Develops trispecific T-cell engagers for autoimmune diseases. | $62M | Q2 2026 | Source |
| Ollin Biosciences | Develops bispecific antibodies for retinal diseases. | $330M | Q2 2026 | Source |
| RQ Bio | Develops long-acting antibodies to prevent respiratory viral infections. | $115M | Q2 2026 | Source |
| Osanni Bio | Develops treatments for eye, heart, and cancer conditions. | $190M | Q2 2026 | Source |
| Serapha Bio | Develops a treatment for alpha-1 antitrypsin deficiency. | $230M | Q2 2026 | Source |
| Nura Bio | Develops SARM1 inhibitors for ALS and nerve degeneration. | $73.8M | Q2 2026 | Source |
| Memento Medicines | Develops bispecific treatments for diabetic macular edema and wet AMD. | $93M | Q2 2026 | Source |
| Triveni Bio | Develops bispecific medicines for atopic dermatitis and immune diseases. | $65M | Q2 2026 | Source |
| SonoThera | Uses ultrasound to deliver genetic medicines into targeted tissues. | $125M | Q2 2026 | Source |
| Ethyreal Bio | Develops biologics for thyroid eye disease and Graves’ disease. | $101M | Q2 2026 | Source |
| City Therapeutics | Develops RNA interference medicines for serious diseases. | $99.5M | Q2 2026 | Source |
| Ona Therapeutics | Develops antibody-drug conjugates for treatment-resistant cancers. | $86.6M | Q2 2026 | Source |
| Contraline | Develops a long-lasting, non-hormonal male contraceptive. | $92.5M | Q2 2026 | Source |
| NewLimit | Develops epigenetic reprogramming therapies for age-related decline. | $435M | Q2 2026 | Source |
| StrainX Bioworks | Uses synthetic biology and fermentation to produce biological ingredients. | $13M | Q2 2026 | Source |
| Accro Bioscience | Develops RIPK2 inhibitors and other immune-disease medicines. | $50M | Q2 2026 | Source |
| Create Medicines | Develops in vivo CAR-T and immune-cell reprogramming therapies. | $122M | Q2 2026 | Source |
| Isomorphic Labs | Uses artificial intelligence to design new medicines. | $2.1B | Q2 2026 | Source |
| CellCentric | Develops an epigenetic cancer treatment for multiple myeloma. | $220M | Q2 2026 | Source |
| Cytospire Therapeutics | Develops gamma-delta T-cell engagers for solid tumors. | $83M | Q2 2026 | Source |
| Windward Bio | Develops long-acting antibodies for asthma and other immune diseases. | $165M | Q2 2026 | Source |
| Vivacta Bio | Develops in vivo CAR-T therapies for cancer and immune diseases. | $50M+ | Q2 2026 | Source |
| Coultreon Biopharma | Develops small-molecule treatments for autoimmune diseases. | $125M | Q2 2026 | Source |
| Fathom Therapeutics | Uses physics and artificial intelligence to design small-molecule medicines. | $47M | Q2 2026 | Source |
| Tortugas Neuroscience | Develops clinical-stage medicines for neuropsychiatric disorders. | $106M | Q2 2026 | Source |
| Ray Therapeutics | Develops optogenetic gene therapies for retinal degeneration. | $125M | Q2 2026 | Source |
| Serif Biomedicines | Develops modified-DNA technology for genetic medicines. | $50M | Q2 2026 | Source |
| Storm Therapeutics | Develops inhibitors of RNA-modifying enzymes for cancer. | $56M | Q2 2026 | Source |
| Terremoto Biosciences | Develops covalent small-molecule medicines for cancer and other diseases. | $108M | Q2 2026 | Source |
| Beeline Medicines | Develops precision medicines for autoimmune and inflammatory diseases. | $300M | Q2 2026 | Source |
| Alloy Therapeutics | Provides biotechnology discovery platforms for antibodies and genetic medicines. | $40M | Q2 2026 | Source |
| Signadori Bio | Develops off-the-shelf immune-cell therapies for solid tumors. | $12.9M | Q2 2026 | Source |
| Adcendo | Develops antibody-drug conjugates for cancer. | $75M | Q2 2026 | Source |
| Neomorph | Develops molecular-glue degraders for cancer and difficult targets. | $100M | Q2 2026 | Source |
| Vivatides Therapeutics | Develops RNA medicines that reach tissues beyond the liver. | $54M | Q2 2026 | Source |
| Oricell Therapeutics | Develops CAR-T therapies for liver cancer and other cancers. | $110M | Q2 2026 | Source |
| Life Biosciences | Develops partial epigenetic reprogramming therapies for age-related diseases. | $80M | Q2 2026 | Source |
| Sidewinder Therapeutics | Develops bispecific antibody-drug conjugates for solid tumors. | $137M | Q2 2026 | Source |
| Stipple Bio | Develops tumor-targeted antibody-drug conjugates. | $100M | Q2 2026 | Source |
| Syneron Bio | Uses artificial intelligence to discover macrocyclic peptide medicines. | $150M | Q2 2026 | Source |
| Ambrosia Biosciences | Develops oral small-molecule GLP-1 treatments. | $100M | Q1 2026 | Source |
| Oncomatryx | Develops antibody-drug conjugates targeting the tumor microenvironment. | $67M | Q1 2026 | Source |
| Gilgamesh Pharma | Develops medicines for neuropsychiatric disorders. | $60M | Q1 2026 | Source |
| Immutrin | Develops antibodies for transthyretin amyloidosis and related heart disease. | $87M | Q1 2026 | Source |
| Earendil Labs | Uses artificial intelligence to discover and develop biologic medicines. | $787M | Q1 2026 | Source |
| Crossbow Therapeutics | Develops T-cell engagers for blood cancers. | $77M | Q1 2026 | Source |
| R1 Therapeutics | Develops treatments for high phosphate levels in dialysis patients. | $77.5M | Q1 2026 | Source |
| Prolium Bioscience | Develops T-cell engagers for severe autoimmune diseases. | $50M | Q1 2026 | Source |
| QL Biopharm | Develops long-acting medicines for obesity and metabolic diseases. | $72.9M | Q1 2026 | Source |
| Atrium Therapeutics | Develops siRNA medicines for serious diseases. | $270M | Q1 2026 | Source |
| BreezeBio | Develops mRNA therapies that restore immune tolerance in type 1 diabetes. | $60M | Q1 2026 | Source |
| Slate Medicines | Develops antibody therapies for migraine and headache disorders. | $130M | Q1 2026 | Source |
| Altesa BioSciences | Develops antiviral medicines for rhinovirus and COPD flare-ups. | $75M | Q1 2026 | Source |
| Korsana Biosciences | Develops brain-penetrant medicines for neurodegenerative diseases. | $175M | Q1 2026 | Source |
| ILiAD Biotechnologies | Develops a next-generation vaccine against pertussis. | $115M | Q1 2026 | Source |
| QuantX Biosciences | Develops oral immune-disease medicines targeting STAT6 and IL-17. | $85M | Q1 2026 | Source |
| Aerska | Develops RNA medicines that cross the blood-brain barrier. | $39M | Q1 2026 | Source |
| Pandorum Technologies | Develops programmable tissue-regeneration therapies. | $18M | Q1 2026 | Source |
| Angitia Biopharmaceuticals | Develops biologic medicines for bone diseases. | $130M | Q1 2026 | Source |
| Third Arc Bio | Develops multifunctional antibodies for cancer and immune diseases. | $52M | Q1 2026 | Source |
| Tenpoint Therapeutics | Develops medicines for presbyopia and other eye diseases. | $85M | Q1 2026 | Source |
| Breakthru Medicine | Develops molecular-glue medicines and cancer drug payloads. | $60M | Q1 2026 | Source |
| TRexBio | Develops regulatory T-cell medicines for autoimmune diseases. | $50M | Q1 2026 | Source |
| Corxel Pharmaceuticals | Develops oral GLP-1 medicines for obesity and diabetes. | $287M | Q1 2026 | Source |
| Mendra | Uses artificial intelligence to build rare-disease treatment programs. | $82M | Q1 2026 | Source |
| Think Bioscience | Develops small-molecule medicines for genetically driven diseases. | $55M | Q1 2026 | Source |
| Exciva | Develops treatments for agitation in Alzheimer’s disease. | $59M | Q1 2026 | Source |
| Cytotheryx | Develops liver-cell therapies and bioartificial liver support. | $60M | Q1 2026 | Source |
| Proxima | Uses artificial intelligence to develop proximity-based medicines. | $80M | Q1 2026 | Source |
| Converge Bio | Uses generative artificial intelligence for drug discovery. | $25M | Q1 2026 | Source |
| Juvena Therapeutics | Develops regenerative biologics using artificial intelligence. | $33.5M | Q1 2026 | Source |
| Vibrant Therapeutics | Develops masked T-cell engagers for solid tumors. | $61M | Q1 2026 | Source |
| Kinaset Therapeutics | Develops inhaled JAK inhibitors for asthma and respiratory diseases. | $103M | Q1 2026 | Source |
| AirNexis Therapeutics | Develops clinical-stage medicines for respiratory diseases. | $200M | Q1 2026 | Source |
| Medipost | Develops stem-cell therapy for knee osteoarthritis. | $140M | Q1 2026 | Source |
| Parabilis Medicines | Develops stabilized peptide medicines for difficult disease targets. | $305M | Q1 2026 | Source |
| Alveus Therapeutics | Develops dual-acting medicines for obesity. | $160M | Q1 2026 | Source |
| Diagonal Therapeutics | Develops clustering antibodies for severe genetic disorders. | $125M | Q1 2026 | Source |
| EpiBiologics | Develops bispecific antibodies that remove extracellular disease proteins. | $107M | Q1 2026 | Source |
| Beacon Therapeutics | Develops gene therapies for inherited retinal diseases. | $75M+ | Q1 2026 | Source |
| Soley Therapeutics | Uses artificial intelligence and cell-stress biology to develop cancer medicines. | $200M | Q1 2026 | Source |
| Rakuten Medical | Develops photoimmunotherapy for head and neck cancer. | $100M | Q1 2026 | Source |
| Corsera Health | Develops long-lasting RNA medicines for cardiovascular disease. | $80M | Q1 2026 | Source |
| Poplar Therapeutics | Develops anti-IgE medicines for food allergies and atopic diseases. | $50M | Q1 2026 | Source |
| Syneron Bio | Uses artificial intelligence to discover macrocyclic peptide medicines. | $100M | Q4 2025 | Source |
| Syremis Therapeutics | Develops treatments for neuropsychiatric disorders. | $165M | Q4 2025 | Source |
| Atavistik Bio | Develops allosteric medicines for rare blood disorders. | $120M | Q4 2025 | Source |
| Addition Therapeutics | Develops precise genetic medicines using RNA-mediated gene insertion. | $100M | Q4 2025 | Source |
| Aeovian Pharmaceuticals | Develops selective mTORC1 inhibitors for neurological and age-related diseases. | $55M | Q4 2025 | Source |
| Ambros Therapeutics | Develops treatments for complex regional pain syndrome. | $125M | Q4 2025 | Source |
| Chai Discovery | Uses artificial intelligence to design therapeutic molecules. | $130M | Q4 2025 | Source |
| Link Cell Therapies | Develops logic-gated CAR-T therapies for cancer. | $60M | Q4 2025 | Source |
| Prolynx | Develops long-acting medicines for metabolic diseases. | $70M | Q4 2025 | Source |
| D3 Bio | Develops KRAS inhibitors and other small-molecule cancer treatments. | $108M | Q4 2025 | Source |
| BlossomHill Therapeutics | Develops small-molecule therapies for cancer. | $84M | Q4 2025 | Source |
| SanegeneBio | Develops RNA interference medicines for genetic and metabolic diseases. | $110M | Q4 2025 | Source |
| OTR Therapeutics | Develops oncology medicines through a Shanghai-based biotechnology platform. | $100M | Q4 2025 | Source |
| SciNeuro Pharmaceuticals | Develops treatments for neurodegenerative diseases. | $53M | Q4 2025 | Source |
| Triana Biomedicines | Develops molecular-glue medicines that remove disease-causing proteins. | $120M | Q4 2025 | Source |
| Aspen Neuroscience | Develops personalized neuron-replacement therapy for Parkinson’s disease. | $115M | Q4 2025 | Source |
| Profluent | Uses artificial intelligence to design proteins and gene-editing systems. | $106M | Q4 2025 | Source |
| Solve Therapeutics | Develops antibody-drug conjugates and related cancer technologies. | $120M | Q4 2025 | Source |
| Artios Pharma | Develops cancer medicines targeting DNA-damage response pathways. | $115M | Q4 2025 | Source |
| Azalea Therapeutics | Engineers cells inside patients using genome editing. | $82M | Q4 2025 | Source |
| Neok Bio | Develops bispecific antibody-drug conjugates for cancer. | $75M | Q4 2025 | Source |
| AAVantgarde Bio | Develops AAV gene therapies for inherited retinal diseases. | $141M | Q4 2025 | Source |
| Hemab Therapeutics | Develops treatments for rare bleeding and clotting disorders. | $157M | Q4 2025 | Source |
| Electra Therapeutics | Develops antibody treatments for rare immune diseases. | $183M | Q4 2025 | Source |
| Elevara Medicines | Develops therapeutics for rheumatoid arthritis. | $70M | Q4 2025 | Source |
| Lila Sciences | Builds artificial-intelligence-powered automated research laboratories. | $115M | Q4 2025 | Source |
| Tr1X | Develops off-the-shelf cell therapies for autoimmune and inflammatory diseases. | $50M | Q4 2025 | Source |
| Excellergy | Develops inhibitors for allergic and immune-cell responses. | $70M | Q4 2025 | Source |
This market map, featured in our biotechnology market deck, highlights top companies and startups in the biotechnology market
Related blog posts
- What has changed recently in the biotechnology market?
- The latest news in the biotechnology market
- What is the true size of the biotechnology market?
- The latest funding news in the biotechnology market
- What are the key fundraising trends in the biotechnology market?
- How funding activity has changed in the biotechnology market
